Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants  by Kaliappan, Saravanakumar Puthupalayam et al.
Vaccine 34 (2016) 4979–4984Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineFactors determining anti-poliovirus type 3 antibodies among orally
immunised Indian infantshttp://dx.doi.org/10.1016/j.vaccine.2016.08.032
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations: tOPV, trivalent oral polio vaccine; PV3, poliovirus serotype 3;
WHO, World Health Organization; MLR, multilevel logistic regression; SD, standard
deviation; CI, confidence interval; OR, odds ratio; OPV, oral poliovirus vaccine;
mOPV3, serotype-3 monovalent oral poliovirus vaccine; IPV, inactivated poliovirus
vaccine; HSC, health sub-centre; PHC, primary health centre; SIA, supplemental
immunisation activity; CDC, Centers for Disease Control and Prevention; TCID50,
median tissue culture infective dose; IQR, interquartile range; v2, Chi-square.
⇑ Corresponding author at: Division of Gastrointestinal Sciences, Christian
Medical College, Vellore, TN 632004, India.
E-mail addresses: saravanakumar@cmcvellore.ac.in (S.P. Kaliappan),
srinistat09@gmail.com (S. Venugopal), sidharthgiri@cmcvellore.ac.in (S. Giri),
irapraharaj@cmcvellore.ac.in (I. Praharaj), arun.karthikeyan@cmcvellore.ac.in
(A.S. Karthikeyan), sudhirbabji@cmcvellore.ac.in (S. Babji), jacob@cmcsph.org
(J. John), jpmuliyil@gmail.com (J. Muliyil), n.grassly@imperial.ac.uk (N. Grassly),
gkang@cmcvellore.ac.in (G. Kang).Saravanakumar Puthupalayam Kaliappan a, Srinivasan Venugopal a, Sidhartha Giri a, Ira Praharaj a,
Arun S. Karthikeyan a, Sudhir Babji a, Jacob John b, Jayaprakash Muliyil a, Nicholas Grassly c,
Gagandeep Kang a,⇑
aDivision of Gastrointestinal Sciences, Christian Medical College, Vellore, India
bDepartment of Community Health, Christian Medical College, Vellore, India
cDepartment of Infectious Disease Epidemiology, Imperial College London, United Kingdom
a r t i c l e i n f oArticle history:
Received 20 May 2016
Received in revised form 3 August 2016
Accepted 11 August 2016







Indiaa b s t r a c t
Background: Among the three poliovirus serotypes, the lowest responses after vaccination with trivalent
oral polio vaccine (tOPV) are to serotype 3. Although improvements in routine immunisation and supple-
mentary immunisation activities have greatly increased vaccine coverage, there are limited data on anti-
body prevalence in Indian infants.
Methods: Children aged 5–11 months with a history of not having received inactivated polio vaccine
were screened for serum antibodies to poliovirus serotype 3 (PV3) by a micro-neutralisation assay
according to a modified World Health Organization (WHO) protocol. Limited demographic information
was collected to assess risk-factors for a lack of protective antibodies. Student’s t-test, logistic regression
and multilevel logistic regression (MLR) model were used to estimate model parameters.
Results: Of 8454 children screened at a mean age of 8.3 (standard deviation [SD]-1.8) months, 88.1% (95%
confidence interval (CI): 87.4–88.8) had protective antibodies to PV3. The number of tOPV doses received
was the main determinant of seroprevalence; the maximum likelihood estimate yields a 37.7% (95% CI:
36.2–38.3) increase in seroprevalence per dose of tOPV. In multivariable logistic regression analysis
increasing age, male sex, and urban residence were also independently associated with seropositivity
(Odds Ratios (OR): 1.17 (95% CI: 1.12–1.23) per month of age, 1.27 (1.11–1.46) and 1.24 (1.05–1.45)
respectively).
Conclusion: Seroprevalence of antibodies to PV3 is associated with age, gender and place of residence, in
addition to the number of tOPV doses received. Ensuring high coverage and monitoring of response are
essential as long as oral vaccines are used in polio eradication.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The global incidence of polio cases has declined with only two
countries now considered polio endemic [1]. This remarkable
reduction was achieved by the effective use of vaccines, with oral
poliovirus vaccines (OPV) playing the greatest role in decreasing
disease and interruption of transmission in developing countries.
Although OPV has many practical advantages for mass immunisa-
tion in field settings [2], like other oral vaccines the immunogenic-
ity and effectiveness of OPV is impaired in lower-income countries
[3–5]. Potential contributing factors for low immunogenicity in
these settings include a high prevalence of diarrhoea, infection of
the gut with other pathogens, malnutrition, micronutrient defi-
ciencies, and tropical enteropathy [3,6].
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vert following administration of OPV after adjusting for potential
confounders like season, breast feeding, mass campaigns and
maternal antibodies [7]. In northern India, reduced take of OPV
was significantly associated with season [8]. Concurrent enteric
infections with lower OPV response in low-income settings have
been described [9,10]. Tropical enteropathy, resulting from high
environmental exposure to enteric pathogens, is common among
children living in poverty and may be associated with poor
response to oral vaccines, both in terms of primary antibody
response and its longevity [11].
Serological data are informative about vaccination coverage,
immunogenicity, secondary spread of vaccine poliovirus and expo-
sure to wild-type infections. However, there are limited published
data available on antibodies to polio in Indian children in the
recent past, particularly from southern India. Table 1 presents a
comparison of recent data on seroprevalence from developing
countries.
After vaccination with tOPV, antibody responses are greatest to
poliovirus type 2 and usually lowest to serotype 3 (PV3) [3]. In
2009, the baseline seroprevalence of antibodies to PV3 among
infants aged 6–9 months was just 48% in a community-based ran-
domised clinical trial conducted in a high risk area, Moradabad in
northern India [12].
We now report a community-based seroprevalence study of
anti-poliovirus type 3 antibodies among infants of age 5–
11 months who had not previously received inactivated poliovirus
vaccination (IPV) residing in rural and urban areas of Vellore dis-
trict of Tamil Nadu, southern India. This study was done to screen
for a clinical trial on the effect of azithromycin on the immuno-
genicity of serotype-3 monovalent oral poliovirus vaccine (mOPV3)
given to healthy infants without antibodies to serotype-3 polio-
virus [10], which found that removal of bacterial pathogens by azi-
thromycin treatment did not increase the proportion of children
who responded to mOPV3.
2. Methods
2.1. Study design and setting
The cross sectional survey was carried out in 210 health sub-
centres (HSC, each serves a population of 5000) of 42 primary
health centres (PHC, each serving approximately 20,000–30,000)
in 14 health blocks (serving 80,000–120,000 and as referral facility
for 3–4 PHCs) of the rural and urban parts of Vellore district of
Tamil Nadu between July 2014 and January 2015.
Infants in the study area receive routine immunisation either
from government or private health care facilities, tOPV is given
with BCG at birth and at 6, 10 and 14 weeks along with DPT in
the study area. IPV was not available in the government sector dur-
ing the study period. The last supplemental immunisation activity
(SIA) was in February 2014 and no SIAs were carried out during the
study period.Table 1
Type specific seroprevalence of anti-poliovirus antibodies among infants in lower and upp
Place World Bank Income classification Year of study A
Egypt Lower middle income 2004 6
Moradabad, India Lower middle income 2007 6
Islamic republic of Iran Upper middle income 2010 7
Kano, Northern Nigeria Lower middle income 2011 6
Northern India Lower middle income 2010 6
Pakistan Lower middle income Published in 2013 6
Sri Lanka Lower middle income 2014 9The Christian Medical College Institutional Review Board and
the Imperial College Research Ethics Committee approved the
study and appropriate central and state governmental permissions
were obtained prior to conducting the screening. Investigators and
study coordinators met with local community leaders, private and
government health providers and informed them about the study
and requested their cooperation.2.2. Study population
We did a door to door survey to identify infants and written
informed consent was obtained from all willing parents of eligible
healthy infants aged between 5 and 11 months. The Village Health
Nurses (VHNs) of the concerned Health sub-centres discussed the
study with potential participants and motivated the families to
participate. A screening camp was organised in each village, and
parents brought the child to the camp. Each infant was assigned
a unique screening identification number and basic demographic
details were collected. A study physician examined the infant for
eligibility for screening and recorded the infant’s age and polio vac-
cination history from the immunisation cards. Additional doses
received during National Immunization Days were obtained from
verbal history as these doses are not recorded on immunisation
cards and if immunisation cards were not available, the mother’s
statement was recorded. Exclusion criteria included children who
had received IPV-through private healthcare providers, had any
congenital or chronic illness or had high grade fever or any other
illness that prevented participation as decided by the study physi-
cian. Infants temporarily excluded because of minor illnesses were
asked to visit the camp held in a neighbouring village.2.3. Laboratory methods
Blood specimens were collected by trained phlebotomists and
study nurses. Samples were stored on ice and delivered to the
laboratory on the same day. Assessment of poliovirus-specific
neutralising antibodies to serotype 3 was done using a micro-
neutralisation assay according to the World Health Organization
(WHO) protocol with modifications [13]. Briefly, a 2-fold dilution
of each serum sample (50 ll) ranging from 1/4 to 1/8 was mixed
with 50 ll of approximately 100 median tissue culture infective
dose (TCID50) of Sabin 3 poliovirus in replicate wells at each dilu-
tion and the mixture was incubated at 37 C (5% CO2) for 1 h.
100 ll of Vero cell suspension (5000 cells/well) was then added
to all the wells and the plates were incubated for 3 days at 37 C
(5% CO2). As part of quality control, standard polio antisera from
the U.S. Centers for Disease Control and Prevention were included
in each run. For each assay, a back-titration titre of 30–300 TCID50
was considered acceptable. Cell controls were included in each
assay. A reciprocal titre of <8 was considered non-protective.er middle income countries.
ge group Sample size Sero prevalence References
Type 1 (%) Type 2 (%) Type 3 (%)
–11 months 973 99.0 99.0 91.0 [36]
–12 months 467 88.0 70.0 75.0 [19]
months 72 84.7 95.8 70.8 [37]
–9 months 161 81.0 75.0 73.0 [22]
–7 months 1280 98.0 66.0 77.0 [38]
–11 months 554 96.0 87.9 86.7 [39]
–11 months 100 96.0 98.0 85.0 [15]
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2.4.1. Data management and analysis
Single data entry of the questionnaire was done using Epi-Info
3.5.1 (CDC, GA, USA) and was verified by a statistician. SPSS 18
(SPSS Inc., IL, USA) and STATA 13 (StataCorp, TX, USA) software
were used for analysis. All statistical tests were carried out at 5%
significance level (p < 0.05) and confidence interval (CI) set at
95%. Student’s t-test was used to compare means. Univariable
and multivariable logistic regression was performed on sex, age,
number of OPV doses received and place of residence and odds
ratio (with 95% CI) calculated to ascertain the strength of associa-
tion between the exposure and outcome variable. In addition, mul-
tilevel logistic regression (MLR) was performed to examine the
effect of contextual (location, period, administrative) and composi-
tional (individual variation) effects on model parameter estimates
[14]. We estimated the probability of seroconversion for each dose
of OPV using the binomial likelihood function, allowing for an arbi-
trary baseline level of seroprevalence among infants who were
reported to have received OPV.3. Results
3.1. Baseline characteristics
Of 12609 children in the target age group invited to participate;
429 (3%) refused participation, 1224 (10%) had received IPV, 2150
(17%) did not visit camp sites because they were unlikely to be
available and 352 (3%) were screen failures based on medical
grounds (congenital heart disease, fever, etc.). Samples were col-
lected from 8454 children from 10 rural health blocks and 4 urban
health centres with an average of 604 children per block (range
89–1184), with a mean age of 8.3 (SD-1.8) months. Baseline char-
acteristics of the study population are shown in Table 2.
3.2. Seroprevalence
The overall seroprevalence of PV3 antibodies was 88.1% (95% CI:
87.4–88.8), 89.2% (95% CI: 88.3–90.1) for males and 87.0% (95% CI:
85.9–88.0) among females (p - <0.0001). Of the 8449 subjects for
whom immunisation status was recorded (median, 4 doses;
interquartile range [IQR], 4–6 doses), children who received fewer
doses had lower seroprevalence, with the lowest 20% (95% CI:
0.5–71.6) among children who reported receiving no dose.Table 2
Baseline characteristic of the study population.
Characteristic Number of children screened Percentage
seroprevalence for
PV3 (95% CI)
Total 8454 88.1 (87.4–88.8)
Age, months
5 862 81.8 (79.0–84.3)
6 1633 81.9 (79.9–83.7)
7 1453 84.5 (82.5–86.3)
8 1312 89.0 (87.2–90.7)
9 1222 92.1 (90.4–93.5)
10 1261 95.7 (94.5–96.8)
11 711 95.9 (94.2–97.3)
Sex
Male 4366 89.2 (88.3–90.1)
Female 4088 87.0 (85.9–88.0)
Area
Urban 2127 89.3 (87.9–90.6)
Rural 6327 87.8 (86.9–88.6)
CI-confidence interval.The estimated probability of seroconversion with each reported
dose of OPV was 37.7% (95% CI: 36.7–38.3), with an estimated
baseline seroprevalence of 3.6% (95% CI: 3.2–4.0) (Fig. 1).
The mean age of seropositive children was higher than seroneg-
ative children (8.4 months, 95% CI: 7.4–7.6 vs. 7.5 months, 95% CI:
8.4–8.5, p < 0.001, t-test). When stratified by month of age, 5-
month old children had the lowest seroprevalence 81.8% (95% CI:
79.0–84.3), seroprevalence increased with age and was 95.9%
(95% CI: 94.2–97.3) for the 11 month olds. Chi-square (v2) value
for linear trends (extended Mantel Haenszel test) for age and num-
ber of OPV doses were 232.5 (p < 0.001) and 336.8 (p < 0.001)
respectively. PV3 seropositivity trend analysis for mean age and
mean number of OPV doses is shown in Fig. 2.
There was no difference in seroprevalence between rural (5552,
87.8%) and urban (1899, 89.3%) children in the univariable analysis
(p = 0.059). Seroprevalence was different across the health blocks,
ranging from 82.1% (95% CI: 79.2–84.8) to 92.55% (95% CI: 87.3–
96.1), as listed in Table 3. Comparison of standard and MLR of null
model revealed significant unexplained heterogeneity (likelihood-
ratio v2 = 40.57 with 1 degree of freedom; p = <0.001) across
blocks.3.3. Univariable and multivariable regression
The results of the univariable, multivariable and multivariable
mixed effects logistic regression analysis are presented in Table 4.
In the multivariable regression, male children were more likely to
be seropositive (OR 1.27, 95% CI: 1.11–1.46). In this same model,
children had higher odds for PV3 seropositivity for each month
increase in age (OR 1.17, 95% CI: 1.12–1.23) and one dose increase
of OPV (OR 1.74, 95% CI: 1.61–1.89). Similarly children residing in
urban areas had higher odds of being seropositive compared to
rural children (OR 1.24, 95% CI: 1.05–1.45) in the standard multi-
variable regression analysis but this was not significant when anal-
ysed in the multivariable mixed effects logistic regression at the
block level (OR 1.18, 95% CI: 0.98–1.41). The mixed effects regres-
sion performed to investigate the cluster effect at various levels
show a significant random effects at the block level (likelihood-
ratio v2 = 11.3 with 1 degree of freedom; p = 0.0004) and not at
the PHC and HSC levels. However, we did not find any appreciable
changes in the parameter estimates.4. Discussion
The seroprevalence among infants of age 5–11 months in rural
and urban areas of Vellore district of Tamil Nadu who had not pre-
viously received IPV was 88.1% (95% CI: 87.4–88.8). This is similar
to rates in Pakistan (Table 1), but slightly lower than in Sri Lanka
[15].
The seroprevalence increased with number of OPV doses
received and is comparable to the seroconversion rates reported
by John [16] and in concurrence with Indian [17–19] and other
studies [20–23]. Similar to other studies, seroprevalence rates
increased with age [19,21,24,25]. This could be due to a more
mature immune system or to receipt of OPV doses that are not
recorded in the vaccination history taken for the child.
Interestingly, there was limited variability in seroprevalence
rates across the various rural and urban blocks (Table 3), demon-
strating that the Tamil Nadu’s state immunisation system is able
to substantially deliver vaccines.
Our study demonstrated that urban infants have higher sero-
prevalence which may be due to increased coverage, accessibility
and higher literacy rates. This is similar to a Mexican study where
urban children had higher antibody prevalence rates (88.2%) than
Fig. 1. Seroprevalence of anti-poliovirus type 3 antibodies by number of OPV doses compared with binomial maximum likelihood model. Estimates reported by John TJ 1976
[16] from the same area are shown by way of comparison.
Fig. 2. Seroprevalence of anti-poliovirus type 3 antibodies by mean number of OPV doses and age among orally immunised Indian infants.
Table 3
Seroprevalence of anti-poliovirus type 3 antibodies by health block and mean number of oral poliovirus vaccine doses received among the study population.
Health block name Seroprevalence (%) Number of screened children Mean number of OPV doses
Alamelumangapuram 149(92.6) 161 5.1
Ambedkarnagar 77(86.5) 89 4.6
Anaicut 1061(89.6) 1184 4.9
Arcot 935(89.5) 1045 4.7
Kaniyambadi 751(91.8) 818 5.0
Kaspa 196(88.7) 221 4.3
Katpadi 488(89.1) 548 4.8
Kaveripakkam 735(84.0) 875 4.4
Lakshmipuram 190(92.2) 206 4.8
Nemili 611(82.1) 744 4.3
Ranipet 171(87.7) 195 4.5
Thimiri 502(84.5) 594 4.9
Ussoor 822(87.7) 937 4.9
Walajah 763(91.2) 837 4.7
Overall 7451(88.1) 8454
OPV-oral poliovirus vaccine.
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Table 4
Factors associated with seroprevalence of anti-poliovirus type 3 antibodies by univariable, multivariable and multilevel multivariable logistic regression analysis among orally
immunised Indian infants (N = 8454 for Unadjusted values except No. of OPV doses; N = 8449 for adjusted values since OPV status not available for 5 children).




p value Odds Ratio
(95% CI)
p value Odds Ratio
(95% CI)
p value Odds Ratio
(95% CI)





1.24 (1.08–1.41) 0.002 1.27 (1.11–1.46) 0.001 1.27 (1.11–1.46) 0.001 1.27 (1.11–1.46) 0.001 1.27 (1.11–1.45) 0.001
Age in months 1.37 (1.31–1.43) <0.001 1.17 (1.12–1.23) <0.001 1.17 (1.12–1.23) <0.001 1.17 (1.12–1.23) <0.001 1.17 (1.12–1.23) <0.001
No. of tOPV doses 1.94 (1.80–2.09) <0.001 1.74 (1.61–1.89) <0.001 1.74 (1.60–1.89) <0.001 1.73 (1.59–1.88) <0.001 1.72 (1.58–1.87) <0.001
Area Urban 1.16 (0.99–1.36) 0.059 1.24 (1.05 –1.45) 0.010 1.24 (1.05– 1.46) 0.012 1.25 (1.05– 1.49) 0.013 1.18 (0.98–1.41) 0.087
Constant 0.0969128 0.0970927 0.0971074 0.1109489
2Log Likelihood 2853.48 2853.45 2851.90 2847.82
Chibar2(01) 0.06 3.16 11.33
Prob of Chibar2 > 0 0.4012 0.0376 0.0004
CI – Confidence Interval HSC – Health Sub-centre PHC – Primary Health Centre.
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report no difference by place of residence [26,27].
Seroprevalence was marginally higher (89.2%) in males com-
pared to females (87.0%) consistent with another study [22], but
differing from Nigeria where females had higher antibody titres
for all the three serotypes in one study [28] or were not different
[29] and a Chinese study that also found no difference [30]. Sex dif-
ferential non-specific effects of vaccines are common in developing
countries with negative non-specific effects (NSE) of inactivated
vaccines more common in girls than boys [31,32] in some coun-
tries, but with no differences in high income countries [33].
Though the general pattern is both negative and positive NSE are
stronger in females [34], a randomised controlled trial in Guinea-
Bissau negated the hypothesis that mortality rates in boys would
be lower if they had not received OPV0 [35]. The reasons why
OPV uptake is slightly higher for males in our study area are
unknown.
Though factors such as age, gender and urban setting have no
remedial solution from a public health perspective, this study indi-
cates that response may be affected by factors that are not amen-
able to modification. This is important for the understanding of
oral vaccine performance in low-income countries.5. Limitation
One of the limitations of this study was that we were unable to
collect more detailed demographic information, morbidity and
nutritional status, other than the physician’s assessment because
of logistic constraints.6. Conclusion
To our knowledge this is the largest seroprevalence study in a
low income setting in a narrow age range. Seroprevalence was
associated with age, gender, number of OPV doses received and
place of residence. The high rate of seropositivity to the weakest
antigen in the trivalent OPV in recent studies in India differs mark-
edly from older studies where low rates of seropositivity to this
antigen were reported. Perhaps the recent switch from tOPV to
bOPV will further increase immunogenicity to type 3 by elimina-
tion of the interference by type 2.
India has seen improvements in immunisation coverage such
that seroprevalence is now reasonable. However, immunogenicity
remains lower than in high-income countries, consistent
with results for other oral vaccines. For future oral vaccines,understanding the reasons for poor performance in low-income
settings remains important.Authors’ contributions
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